NiCox and Pfizer launch glaucoma trial

January 8, 2008

NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.

NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.

PF-03187207 is the lead development compound generated under the collaboration between Pfizer and NicOx, which is concentrating on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.

The Japanese study will compare the safety and efficacy of the PF-03187207 with latanoprost (Xalatan; Pfizer). The compound is already being examined in a Phase II proof-of-concept study in the US.